摘要
Abstract
OBJECTIVE: To evaluate the efficacy and safety of Kang' ai injection combined with chemotherapy on non-small cell lung cancer systematically. METHODS: According to the requirements of evidence-based medicine, retrieved from VIP, CNKI and CBM. 23 domestic published RCTs about Kang' ai injection combined with chemotherapy on non-small cell lung cancer during 1994 -2011 were retrieved and included in Meta-analysis. RevMan 4.2 (Review manager) software provided by Cochrane collaboration net was applied for data processing and statistical analysis. RESULTS: 23 studies were involved in Meta-analysis. Compared with the control group, the results of combined test of effective rate, quality of life, clinical symptoms and leucocytopenia were as follows: [RR=1.66, 95% CI (1.35, 2.03)], [RR=3.22, 95% CI (2.55, 4.06)], [RR=4.24, 95% CI (2.79, 6.46)], [RR=0.36, 95% CI (0.29, 0.46)]. CONCLUSION: From the existing clinical evidences, Kang' ai injection combined with chemotherapy in the treatment of non-small cell lung cancer could enhance the treatment efficacy, improve the life quality of patients and alleviate the side effects of chemotherapy.关键词
康艾注射液/非小细胞肺癌/Meta分析Key words
Kang'ai injection/ Non-small cell lung cancer/ Meta-analysis分类
医药卫生
